|
Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR). |
|
|
Research Funding - Sella Life Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Actinium Pharmaceuticals; Ambit BioSciences; Astellas Pharma; Celgene; Seagen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Juno Therapeutics |
Research Funding - Genentech/Roche (Inst); Juno Therapeutics (Inst) |
|
|
Consulting or Advisory Role - Amgen; Baxalta; Gilead Sciences; Jazz Pharmaceuticals; Pfizer; Spectrum Pharmaceuticals (I) |
Speakers' Bureau - Jazz Pharmaceuticals |
Research Funding - Amgen; Bristol-Myers Squibb; Gilead Sciences; Incyte; Sigma-Tau |
|
|
Employment - Sella Life Sciences |
Leadership - Sella Life Sciences |
|
|
Employment - Sella Life Sciences |
Leadership - Sella Life Sciences |
|
|
Research Funding - BiolineRx; Boehringer Ingelheim; Epizyme |
|
|
Consulting or Advisory Role - Sella Life Sciences |
Research Funding - Sella Life Sciences |
Patents, Royalties, Other Intellectual Property - Sella Life Sciences |